US010377805B2

(12) **United States Patent**
Cujec et al.

(10) **Patent No.: US 10,377,805 B2**
(45) **Date of Patent: *Aug. 13, 2019**

(54) **MODIFIED FGF-21 POLYPEPTIDES COMPRISING NON-NATURALLY ENCODING AMINO ACIDS AND THEIR USES**

(71) Applicant: **AMBRX, INC.**, La Jolla, CA (US)

(72) Inventors: **Thomas P. Cujec**, San Diego, CA (US); **Roberto Mariani**, San Diego, CA (US); **Anna-Maria A. Hays Putnam**, San Diego, CA (US); **William M. Keefe**, Los Angeles, CA (US); **Nick Knudsen**, Escondito, CA (US); **Lillian Skidmore**, San Diego, CA (US); **Jason Pinkstaff**, Encinitas, CA (US); **Vadim Kraynov**, San Diego, CA (US)

(73) Assignee: **AMBRX, INC.**, La Jolla, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/953,091**

(22) Filed: **Apr. 13, 2018**

(65) **Prior Publication Data**

US 2018/0298073 A1 Oct. 18, 2018

Related U.S. Application Data

(62) Division of application No. 15/292,700, filed on Oct. 13, 2016, now Pat. No. 9,975,936, which is a division of application No. 14/680,543, filed on Apr. 7, 2015, now Pat. No. 9,517,273, which is a division of application No. 13/732,522, filed on Jan. 2, 2013, now Pat. No. 9,079,971, which is a division of application No. 13/051,953, filed on Mar. 18, 2011, now Pat. No. 8,383,365, which is a division of application No. 12/051,830, filed on Mar. 19, 2008, now Pat. No. 8,012,931.

(60) Provisional application No. 60/988,060, filed on Nov. 14, 2007, provisional application No. 60/921,297, filed on Mar. 30, 2007.

(51) **Int. Cl.**

C07K 14/50	(2006.01)
A61K 47/60	(2017.01)
A61K 38/18	(2006.01)
A61K 38/00	(2006.01)
A61K 45/06	(2006.01)
C12N 15/70	(2006.01)

(52) **U.S. Cl.**

CPC ***C07K 14/50*** (2013.01); ***A61K 38/1825*** (2013.01); ***A61K 45/06*** (2013.01); ***A61K 47/60*** (2017.08); ***C12N 15/70*** (2013.01); *A61K 38/00* (2013.01); *Y02A 50/473* (2018.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,968,158	A	1/1961	Ruschig et al.
3,097,242	A	7/1963	Hoehn et al.
3,454,635	A	7/1969	Weber et al.
3,501,495	A	3/1970	Beregi et al.
3,654,357	A	4/1972	Bretschneider et al.
3,668,215	A	6/1972	Plumpe et al.
3,669,966	A	6/1972	Ambrogi et al.
3,708,486	A	1/1973	Kutter et al.
3,773,919	A	11/1973	Boswell et al.
4,287,200	A	9/1981	Kawamatsu et al.
4,289,872	A	9/1981	Denkewalter et al.
4,412,989	A	11/1983	Iwashita et al.
4,414,148	A	11/1983	Jansen et al.
4,452,747	A	6/1984	Gersonde
4,485,045	A	11/1984	Regen
4,511,502	A	4/1985	Builder et al.
4,511,503	A	4/1985	Olson et al.
4,512,922	A	4/1985	Jones et al.
4,544,545	A	10/1985	Ryan et al.
4,551,433	A	11/1985	DeBoer
4,569,789	A	2/1986	Blattler et al.
4,572,912	A	2/1986	Yoshioka et al.
4,619,794	A	10/1986	Hauser
4,659,839	A	4/1987	Nicolotti et al.
4,670,417	A	6/1987	Iwasaki et al.
4,671,958	A	6/1987	Rodwell et al.
4,680,338	A	7/1987	Sundoro
4,687,777	A	8/1987	Meguro et al.
4,689,406	A	8/1987	Banks et al.
4,699,784	A	10/1987	Shih et al.
4,738,921	A	4/1988	Belagaje et al.
4,755,465	A	7/1988	Gray et al.
4,820,352	A	4/1989	Riedhammer
4,837,148	A	6/1989	Cregg
4,859,600	A	8/1989	Gray et al.
4,873,080	A	10/1989	Brickl et al.
4,873,255	A	10/1989	Yoshioka et al.
4,876,197	A	10/1989	Burke et al.
4,880,734	A	11/1989	Burke et al.
4,897,405	A	1/1990	Alessi et al.
4,902,502	A	2/1990	Nitecki et al.
4,904,584	A	2/1990	Shaw
4,929,555	A	5/1990	Cregg et al.

(Continued)

FOREIGN PATENT DOCUMENTS

AU	1740283	2/1984
CA	2386517	4/2001

(Continued)

OTHER PUBLICATIONS

Yie J, Wang W, Deng L, Tam LT, Stevens J, Chen MM, Li Y, Xu J, Lindberg R, Hecht R, Véniant M. "Understanding the Physical Interactions in the FGF21/FGFR/β-Klotho Complex: Structural Requirements and Implications in FGF21 Signaling." Chemical biology & drug design. Apr. 1, 2012;79(4):398-410.

(Continued)

Primary Examiner — Elly-Gerald Stoica

(74) *Attorney, Agent, or Firm* — Robin L. Teskin; LeClairRyan PLLC

(57) **ABSTRACT**

Modified FGF-21 polypeptides and uses thereof are provided.

21 Claims, 39 Drawing Sheets

Specification includes a Sequence Listing.